KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Brokerages

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have earned an average recommendation of “Buy” from the five research firms that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $25.00.

KALV has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. TD Cowen initiated coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Finally, Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock.

Insider Buying and Selling

In related news, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now directly owns 94,199 shares of the company’s stock, valued at $872,282.74. This trade represents a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the completion of the sale, the chief executive officer now owns 266,598 shares in the company, valued at approximately $2,468,697.48. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,291 shares of company stock valued at $304,086 over the last quarter. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares in the last quarter. SG Americas Securities LLC lifted its stake in KalVista Pharmaceuticals by 10.0% during the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 1,319 shares during the period. Intech Investment Management LLC bought a new position in KalVista Pharmaceuticals during the 3rd quarter valued at about $126,000. Quest Partners LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $175,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after acquiring an additional 3,314 shares during the period.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $8.77 on Friday. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $16.88. The stock has a market cap of $433.41 million, a P/E ratio of -2.41 and a beta of 0.86. The firm’s fifty day moving average price is $8.86 and its 200-day moving average price is $10.94.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.01. Sell-side analysts predict that KalVista Pharmaceuticals will post -3.56 earnings per share for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).